Posted by Michael Wonder on 08 Dec 2021
Saol Therapeutics announces FDA approval of Lyvispah (baclofen) oral granules
7 December 2021 - Saol Therapeutics today announced that the U.S. FDA has approved Saol's Lyvispah (baclofen) oral granules.
Lyvispah is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
